Diagnostic approach to CLL_Dr Nazim_PPT
-
Upload
aym-nazim -
Category
Health & Medicine
-
view
67 -
download
0
description
Transcript of Diagnostic approach to CLL_Dr Nazim_PPT
![Page 1: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/1.jpg)
1
Presentation on Treatment strategy of CLL: Presentation on Treatment strategy of CLL: Do all CLL patients need treatment?Do all CLL patients need treatment?
Dr. A. Y. Md. NazimDr. A. Y. Md. Nazim
Fellow Trainee-HaematologyFellow Trainee-Haematology
Department of HaematologyDepartment of Haematology
Dhaka Medical College & HospitalDhaka Medical College & Hospital
![Page 2: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/2.jpg)
2
This presentation includes:
CLL definition, Incidence, Clinical features
Diagnosis, Lab-investigation, Staging, Prognostic markers
Classical criteria for treatment,
Conclusion
![Page 3: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/3.jpg)
3
What is chronic lymphocytic leukaemia?
It is a malignant proliferation of
Mature looking
Functionally incompetent
Small lymphocytes
Accumulate in the bone marrow, peripheral blood, lymph nodes, spleen, liver, and sometimes other organ
![Page 4: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/4.jpg)
4
Epidemiology
Commonest leukaemia in Western world (20-30%)Commonest leukaemia in Western world (20-30%)
Predominantly a disease of Predominantly a disease of elderlyelderly
Mean age at diagnosis is 70 yearMean age at diagnosis is 70 year
10% younger than 50 years old10% younger than 50 years old
![Page 5: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/5.jpg)
5
Cause of CLL
Cause of CLL is unknown
No causal relationship with radiation, chemical or viruses
No direct modes of inheritance
Cellular accumulation - basic defect
Defects in intracellular apoptic pathway
90% have high levels of BCL-2
![Page 6: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/6.jpg)
6
Clinical Features
Often asymptomatic at diagnosis
• Painless lymphadenopathy
• Splenomagaly(70%)
• Hepatomegaly(50%)
![Page 7: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/7.jpg)
7
Clinical features Clinical features (contd.)(contd.)
Features of bone marrow failure Anaemia, Thrombocytopenia
Recurrent infection
• Fever and weight loss uncommon
• Para neoplastic syndrome
![Page 8: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/8.jpg)
8
DiagnosisHistory, physical examination & peripheral blood is sufficient for diagnosis of CLL.
![Page 9: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/9.jpg)
9
Diagnosis (Contd.)
Published criteria for CLL Diagnosis:
Peripheral blood lymphocyte count>5000Peripheral blood lymphocyte count>5000 with B cell phenotype consistent with CLLwith B cell phenotype consistent with CLL
Light chain restrictionLight chain restriction
Bone marrow aspirate >30% Bone marrow aspirate >30% lymphocyteslymphocytes
![Page 10: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/10.jpg)
10
Diagnosis (Contd.)
Is bone marrow aspiration necessary for CLL diagnosis?Is bone marrow aspiration necessary for CLL diagnosis?
![Page 12: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/12.jpg)
12
Immunophenotyping findings in CLL
Bcell specific differentiation antigenCD 19+CD 20+CD 22+CD 79a
CD 23+CD 5+ without other pan T marker
sIg weak +
FMC7 -
![Page 13: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/13.jpg)
13
Other laboratory investigations
Hypogammaglobulinaemia
Paraproteinaemia(5%)
Cytogenetic abnormalities in > 80% by FISH
13q-
11q
12+
17p-
![Page 14: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/14.jpg)
14
Other laboratory investigations
LDH
β2 microglobulin
Uric acid
Urea
Creatinine
Eelectrolytes
Imaging as necessary for symptoms
![Page 15: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/15.jpg)
15
Differential Diagnosis• PLL• WM• Leukaemic phase of lymphoma• HCL• Tcell CLL• T-LGL• CTCL
Morphology and Immunophenotyping can differentiate CLL from other LPDs.
![Page 16: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/16.jpg)
16
Do all CLL Do all CLL patients need treatment? need treatment?
Rai clinical Rai clinical staging :Level of risk Stage Median
survival
Low risk 0 Lymphocytosis only > 13 yrs
Intrmediate risk
I Lymphocytosis & lymphadenopathyII Lymphocytosis & Splenomegaly and or Hepatomegaly
5-8 yrs
High risk III Lymphocytosis & anaemia
IV Lymphocytosis & thrombocytopenia 1-2 yrs
![Page 17: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/17.jpg)
17
Do all CLL patients need treatment?Do all CLL patients need treatment?
Binet Binet clinical staging staging:
Stage Clinical features Median survival
A < 3 lymphoid regions enlarged 12 yrs
B 3 or more than 3 lymphoid regions included
5 yrs
C Aanaemia and or thrombocytopenia 2 yrs
![Page 18: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/18.jpg)
18
Variation in prognosis
Median survival of patients with stage A disease or in the low risk group is > 10 years
40% patients progress to advanced disease
50% patients require therapy at some point
25% dying from their disease..
![Page 19: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/19.jpg)
19
Other clinical prognostic factors
Initial lymphocytosis > 50,000
> 5% prolymphocytes
Atypical lymphocyte morphology
Diffuse pattern of infiltrate on trephine
Blood lymphocyte doubling time < 12 months
![Page 20: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/20.jpg)
20
Biologic Prognostic factors
Serum markers:
• Thymidine kinase levels predict disease progression
• Soluble CD-23 levels linked to adverse prognostic • features
• ββ22 microglobulin level shows a positive correlation with
clinical stages
![Page 21: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/21.jpg)
21
CytogeneticsGenetic abnormalities by FISH associated with abnormalities by FISH associated with
progression and poor prognosis in CLL and poor prognosis in CLL
Cytogenetic Abnormality Characteristics of disease
11q23(20% of cases)
Younger age Lymphadenopathyshort survival
12+(15% of cases)
CLL/PL Disease progressionhigh proliferation rate
17p21(7% of cases)
CLL/PL Poor response to therapytransformation
13q(36% of cases)
Excellent prognosis(median survival 133months)
![Page 22: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/22.jpg)
22
IgVH mutational status
IgVH mutational status separates CLL into two different forms of the disease:
IgVH unmutated genes - Progressive disease
IgVH mutated genes - Stable disease
![Page 23: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/23.jpg)
23
Surrogate markers of IgVH mutational status
CD-38 expression - an independent prognostic factor
ZAP-70 expression detected provide stable prognostic information
![Page 24: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/24.jpg)
24
Surrogate markers of IgVH mutational status (Contd)
ZAP-70 and CD-38 may provide complementary prognostic information
Both markers - poorest prognosis
None of the markers - good outcomes
Either of the markers - intermediate
![Page 25: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/25.jpg)
25
Response to therapy
Important prognostic factor for survival
• Higher the degree of response longer the survivalHigher the degree of response longer the survival
• Patients who achieved MRD negative status have a Patients who achieved MRD negative status have a better prognosisbetter prognosis
![Page 26: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/26.jpg)
26
Conclusion
Treatment based on classical criteria (NCI-CLL/WG)
Advanced stage
Symptomatic or unsightly lymphadenopathy
Haemolytic anaemia
Thrombocytopenia
![Page 27: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/27.jpg)
27
Conclusion (Contd.)
Treatment based on classical criteria (NCI-CLL/WG)
• Blood lymphocyte doubling time <6 months
• Prolymphocytic or Richter transformation
Treatment decisions based on biological parameters are justified within clinical trials
![Page 28: Diagnostic approach to CLL_Dr Nazim_PPT](https://reader034.fdocuments.net/reader034/viewer/2022042816/559432a91a28abca7e8b4666/html5/thumbnails/28.jpg)
28